New hope for Tough-to-Treat lung cancer? experimental drug targets KRAS mutation
NCT ID NCT03808558
Summary
This study is testing an experimental oral drug called TVB-2640 in people with advanced non-small cell lung cancer that has a specific genetic change called a KRAS mutation and has stopped responding to standard treatments. The main goals are to see if the drug can control the cancer's growth and to check its safety. Researchers will also use special scans and blood tests to learn more about how the drug works in the body.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS GENE MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Cincinnati
Cincinnati, Ohio, 45267, United States
-
University of Texas Southwestern Medical Center
Dallas, Texas, 75390-9179, United States
Conditions
Explore the condition pages connected to this study.